As filed with the Securities and Exchange Commission on February 12, Washington, D. FORM F. For the fiscal year ended December 31,

Author:Fenridal Tojatilar
Language:English (Spanish)
Published (Last):15 January 2018
PDF File Size:7.3 Mb
ePub File Size:5.85 Mb
Price:Free* [*Free Regsitration Required]

As filed with the Securities and Exchange Commission on February 12, Washington, D. FORM F. For the fiscal year ended December 31, Exact name of Registrant as specified in its charter.

Jurisdiction of incorporation or organization. Schwarzwaldallee , Basel, Switzerland. Address of principal executive offices. James Halliwell. Syngenta International AG. CH Basel, Switzerland. Securities registered or to be registered pursuant to Section 12 b of the Act:. Title of each class. Name of each exchange on which registered.

American Depositary Shares, each representing. New York Stock Exchange. Securities registered or to be registered pursuant to Section 12 g of the Act: None. Securities for which there is a reporting obligation pursuant to Section 15 d of the Act: None. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule of the Securities Act.

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15 d of the Securities Exchange Act of Indicate by check mark whether the registrant 1 has filed all reports required to be filed by Section 13 or 15 d of the Securities Exchange Act of during the preceding 12 months or for such shorter period that the registrant was required to file such reports , and 2 has been subject to such filing requirements for the past 90 days.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:.

International Financial Reporting Standards as issued by the. If this is an annual report, indicate by check mark whether the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. The Transactions were completed on November 13, Investors are cautioned that such forward-looking statements involve risks and uncertainties, and that actual results may differ materially. Syngenta cannot guarantee that any of the events or trends anticipated by the forward-looking statements will actually occur.

Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among other things:. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Syngenta does not intend or assume any obligation to update these forward-looking statements. PART I. Item 2 — Offer Statistics and Expected Timetable. Item 3 — Key Information. Item 4 —— Information on the Company.

Item 4A —— Unresolved Staff Comments. Item 5 — Operating and Financial Review and Prospects. Item 6 — Directors, Senior Management and Employees. Item 8 — Financial Information. Item 9 — The Offer and Listing. Item 10 — Additional Information. Item 13 — Defaults, Dividend Arrearages and Delinquencies. Item 15 — Controls and Procedures. Item 16 — [Reserved]. Item 16B — Code of Ethics. Item 16G — Corporate Governance.

Item 16H — Mine Safety Disclosure. Item 17 — Financial Statements. Item 18 — Financial Statements. Item 19 — Exhibits. Not applicable. Selected Financial Data.

The selected financial highlights information in accordance with IFRS presented below has been extracted from the consolidated financial statements of Syngenta. Investors should read the entire consolidated financial statements and not rely on the summarized information. For further information about these and other acquisitions, see Note 3 to the consolidated financial statements in Item Financial highlights.

Year ended December 31,. Amounts in accordance with IFRS. Income statement data:. Cost of goods sold. Gross profit.

Operating expenses. Operating income. Income before taxes. Net income. Net income attributable to Syngenta AG shareholders. Number of shares — basic. Number of shares — diluted. Cash dividends paid:. Cash flow data:. Cash flow from operating activities. Cash flow used for investing activities. Cash flow used for financing activities. Capital expenditure on tangible fixed assets. Balance sheet data:. Current assets less current liabilities. Total assets. Total non-current liabilities.

Total liabilities. Share capital. Other supplementary income data:. All activities were in respect of continuing operations. Diluted earnings per share from continuing operations, excluding restructuring and impairment is a non-GAAP measure. A non-GAAP measure is a numerical measure of financial performance, financial position or cash flow that either:.

Restructuring includes the incremental costs of closing, restructuring or relocating existing operations, and gains or losses from related asset disposals. Restructuring also includes the effects of completing and integrating significant business combinations and divestments, including related transaction costs, gains and losses.

Recurring costs of normal business operations and routine asset disposal gains and losses are excluded. Impairment includes impairment losses associated with major restructuring as well as impairment losses and reversals of impairment losses resulting from major changes in the markets in which a reported segment operates.

Restructuring and impairment charges for , and are analyzed in Note 6 to the consolidated financial statements in Item Restructuring for and also related to the Operational Efficiency program announced in representing the costs of closure of certain manufacturing and research and development sites and refocusing of other continuing sites and also to the further phase of the Operational Efficiency program announced in to drive cost savings to offset increased expenditure in research and technology, marketing and product development in the growth areas of Seeds, professional products and emerging country markets.

A detailed reconciliation of net income and earnings per share before restructuring and impairment to net income and earnings per share according to IFRS is presented in Appendix A at the end of the Operating and Financial Review and Prospects in Item 5.

Risk Factors. Risks that are considered to be material are described below. The resources Syngenta devotes to research and development may not result in commercially viable products.

Research and development in the agribusiness industry is expensive and prolonged, and entails considerable uncertainty. The process of developing a novel crop protection product, plant variety or trait typically takes around ten years or more from discovery through testing and registration to initial product launch; this period varies considerably from product to product and country to country. Because of the stringent product performance and safety criteria applied in product development, compounds or biotechnological products currently under development may neither survive the development process nor ultimately receive the requisite regulatory approvals needed to market such products.

Even when such approvals are obtained, there can be no assurance that a new product will be commercially successful.


Our crop protection products

Here you will find descriptions of many of our major crop protection products. For the full list of brands available in your country, or label information please visit your country website. Advanced seeds mitigate risks such as disease and drought and allow farmers to grow food using less land, less water and fewer inputs. Home Protecting crops Our crop protection products. Our crop protection products.


The dose formulations test item in the vehicle prepared for dosing the test systems in toxicology studies are required to be analysed for test concentration v This issue has gained considerable attention this week. According to some, the US and Canada are concerned about the issue, while others have commented that it Stepan has recently developed a new class of nonionic, HPP dispersants. Originally designed for and applied to the preparation of pigment dispersions for coatin Envita, containing Gluconacetobacter diazotrophicus, fixes N in corn and other crops beyond legumes.



Related Articles